Autopsy as gold standard in FDG-PET studies in dementia

Canadian Journal of Neurological Sciences

Volumn 37, Issue 3, 2010, Pages 336-342

  Durand Martel, Pascali ^a   Tremblay, Dominic ^a   Brodeur, Catherine ^b   Paquet, Nancy ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; AUTOPSY; DEMENTIA; DIAGNOSTIC ACCURACY; DIFFUSE LEWY BODY DISEASE; FRONTOTEMPORAL DEMENTIA; GOLD STANDARD; HISTOPATHOLOGY; HUMAN; MEDLINE; POSITRON EMISSION TOMOGRAPHY; PRION DISEASE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

EID: 77950643110     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100010222     Document Type: Review

References (70)

1. Chertkow H, Black S. Imaging biomarkers and their role in dementia clinical trials. Can J Neurol Sci. 2007;34 Suppl 1: 77-83.
2. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameters: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1143-1153 (Pubitemid 32405708)
3. Borrie M. Functional neuroimaging in the diagnosis of dementia. Alzheimers Dement. 2007;3:336-340 (Pubitemid 47535134)
4. Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med. 2004;45:594-607.
5. Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. Arch Neurol. 1994;51:1198-1204.
6. Lim A, Tsuang D, Kukull W. Clinico-neuropathological correlation of Alzheimer's disease in a community-Based case series. J Am Geriatr Soc. 1999;47:564-569 (Pubitemid 29215585)
7. Lopez OL, Litvan I, Catt KE, Stowe R, Klunk W, Kaufer DI, et al. Accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias. Neurology. 1999;53(6):1292-1299 (Pubitemid 29480090)
8. Massoud F, Devi G, Stern Y, Lawton A, Goldman JE, Liu Y, et al. A clinicopathological comparison of community-based and clinic-based cohorts of patients with dementia. Arch Neurol. 1999;56:1368-1373 (Pubitemid 29519853)
9. Victoroff J, Mack WJ, Lyness SA, Chui HC. Multicenter clinicopathological correlation in dementia. Am J Psychiatry. 1995;152(10):1476-1484
10. Becker JT, Boller F, Lopez OL, Saxton J, McGonigle KL. The natural history of Alzheimer's disease: description of study cohort and accuracy of diagnosis. Arch Neurol. 1994;51:585-594 (Pubitemid 24169374)
11. Klatka LA, Schiffer RB, Powers JM, Kazee AM. Incorrect diagnosis of Alzheimer's disease: a clinicopathologic study. Arch Neurol. 1996;53:35-42. (Pubitemid 26023282)
12. Mendez MF, Mastri AR, Sung JH, Frey WH 2nd. Clinically diagnosed AD: neuropathologic findings in 650 cases. Alzheimer Dis Assoc Disord. 1992;6:35-43.
13. Forman MS, Farmer J, Johnson JK, Clark CN, Arnold SE, Koslett HB, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59:952-962 (Pubitemid 43830927)
14. Friedland RP, Prusiner SB, Jagust WJ, Budinger TF, Davis RL. Bitemporal hypometabolism in Creutzfeldt-Jakob disease measured by positron emission tomography with [18F]-2-fluorodeoxyglucose. J Comput Assist Tomogr. 1984;8:978-981
15. Goldman S, Liard A, Flament-Durand J, Luxen A, Bidaut LM, Stanus E, et al. Positron emission tomography and histopathology in Creutzfeldt-Jakob disease. Neurology. 1993; 43:1828-1830 (Pubitemid 23307966)
16. Matochik JA, Molchan SE, Zametkin AJ, Warden DL, Sunderland T, Cohen RM. Regional cerebral glucose metabolism in autopsyconfirmed Creutzfeldt-Jakob disease. Acta Neurol Scand. 1995; 91:153-157
17. Ogawa T, Inugami A, Fujita H, Hatazawa J, Shimosegawa E, Kanno I, et al. Serial positron emission tomography with fludeoxyglucose F18 in Creutzfeldt-Jakob disease. Am J Neuroradiol. 1995;16:978-981
18. Holthoff VA, Sandmann J, Pawlik G, Schröder R, Heiss WD. Positron emission tomography in Creutzfeldt-Jakob disease. Arch Neurol. 1990;47:1035-1038 (Pubitemid 20307714)
19. Tanaka Y, Minematsu K, Moriyasu H, Yamaguchi T, Yutani C, Kitamoto T, et al. A Japanese family with a variant of Gerstmann-Sträussler-Scheinker disease. J Neurol Neurosurg Psychiatry. 1997;62:454-457 (Pubitemid 27237052)
20. Hamaguchi T, Kitamoto T, Sato T, Mizusawa H, Nakamura Y, Noguchi M, et al. Clinical diagnosis of MM2-type sporadic Creutzfeldt-Jakob disease. Neurology. 2005;64:643-648 (Pubitemid 40261892)
21. Pichler R, Ciovica I, Rachinger J,Weiss S, Aichneir FT. Multitracer study in Heidenhain variant of Creutzfeldt-Jakob disease: mismatch pattern of cerebral hypometabolism and perfusion imaging. Neuro Endocrinol Lett. 2008;29:67-68
22. McGeer PL, Kamo H, Harrop R, McGeer EG, Martin WR, Pate BD, et al. Comparison of PET, MRI and CT with pathology in a proven case of Alzheimer's disease. Neurology. 1986;36: 1569-1574 (Pubitemid 17199073)
23. McGeer PL, Kamo H, Harrop R, Li DK, Tuokko H, McGeer EG, et al. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. CMAJ. 1986;134:597-607. (Pubitemid 16099652)
24. Kempler D, Metter EJ, Riege WH, Jackson CA, Benson DF, Henson WR. Slowly progressive aphasia: three cases with language, memory, CT and PET data. J Neurol Neurosurg Psychiatry. 1990;53:987-993 (Pubitemid 20378903)
25. Mega MS, Chen SS, Thompson PM, Woods RP, Karaca TJ, Tiwari A, et al. Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease. Neuroimage. 1997;5:147-153 (Pubitemid 27481519)
26. Kile SJ, Ellis WG, Olichney JM, Farias S, DeCarli C. Alzheimer abnormalities of the amygdala with Klüver-Bucy syndrome symptoms. Arch Neurol. 2009;66(1):125-129
27. Kamo H, McGeer PL, Harrop R, McGeer EG, Kalne DB, Martin WR, et al. Positron emission tomography and histopathology in Pick's disease. Neurology. 1987;37(3):439-445 (Pubitemid 17031740)
28. Friedland RP, Koss E, Lerner A, Hedera P, Ellis D, Dronkers N, et al. Functional imaging, the frontal lobes and dementia. Dementia. 1993;4:192-203. (Pubitemid 23234434)
29. Murrel JR, Spillantini MG, Zolo P, Guazzelli M, Smith MJ, Hasegawa M, et al. Tau gene mutation G389R causes a tauopathy with abundant Pick body-like inclusions and axonal deposits. J Neuropathol Exp Neurol. 1999;58(12):1207-1226
30. Spina S, Murrel JR, Huey ED, Wassermann EM, Pietrini P, Grafman J, et al. Corticobasal syndrome associated with theA9D progranulin mutation. J Neuropathol Exp Neurol. 2007;66(10): 892-900. (Pubitemid 47530828)
31. Higuchi M, Tashiro M, Arai H, Okamura N, Hara S, Higuchi S, et al. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol. 2000;162: 247-256 (Pubitemid 30217720)
32. Tatlidil R, New P, Mayberg H. FDG positron emission tomography in diffuse Lewy Body disease; a case report. Clin Nucl Med. 2000;25:1004-1006
33. Hisanaga K, Suzuki H, Tanji H, Mochizuki H, Iwasaki Y, Sato N, et al. Fluoro-DOPA and FDG positron emission tomography in a case of pathologically verified pure diffuse Lewy Body disease. J Neurol. 2001;248:905-906 (Pubitemid 32955678)
34. Bacskai BJ, Frosch MP, Freeman SH, Raymond SB, Augustinack JC, Johnson KA, et al. Molecular imaging with Pittsburg Compound B confirmed at autopsy. Arch Neurol. 2007;64: 431-434
35. Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu XS, et al. [18F]FDG-PET study in dementia with Lewy bodies and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:447-456 (Pubitemid 32236707)
36. Gerstner E, Lazar RM, Keller C, Honig LS, Lazar GS, Marshall RS. A case of progressive apraxia of speech in pathologically verified Alzheimer's disease. Cogn Behav Neurol. 2007;20: 15-20. (Pubitemid 46673706)
37. Stanford PM, Halliday GM, Brooks WS, Kwok JB, Storey CE, Creazy H, et al. Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. Brain. 2000;123:880-893
38. Mizuno T, Shiga K, Nakata Y, Nagura J, Nakase T, Ueda Y, et al. Discrepancy between clinical and pathological diagnoses of CBD and PSP. J Neurol. 2005;252:687-697 (Pubitemid 40864043)
39. Shapiro MB, Pietrini P, Grady CL, Ball MJ, DeCarli C, Kumar A, et al. Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer disease. J Neurol Neurosurg Psychiatry. 1993;56:859-864 (Pubitemid 23246143)
40. Akiyama H, Harrop R, McGeer PL, Peppard R, McGeer EG. Crossed cerebellar and uncrossed thalamic diaschisis in Alzheimer's disease. Neurology. 1989;39:541-548 (Pubitemid 19105771)
41. McGeer EG, McGeer PL, Akiyama H, Harrop R. Cortical glutaminase, beta-glucuronidase and glucose utilization in Alzheimer's disease. Can J Neurol Sci. 1989;16 Suppl 4:511-515 (Pubitemid 19278362)
42. McGeer EG, Peppard RP, McGeer PL, Tuokko H, Crockett D, Parks R, et al. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer's cases, including 13 serial scans. Can J Neurol Sci. 1990;17:1-11. (Pubitemid 20101016)
43. Peppard RF, Martin WR, Clark CM, Karr GD, McGeer PL, Kalne DB. Cortical glucose metabolism in Parkinson's and Alzheimer's disease. J Neurosci Res. 1990;27:561-568
44. Barker WW, Yoshii F, Lowenstein DA, Chang JY, Apicella A, Pascal S, et al. Lack of correlation of regional neuropathology to the regional PET metabolic deficits in Alzheimer's disease. J Cereb Blood Flow Metab. 1991;11 Suppl 2:19.
45. DeCarli C, Atack JR, Ball MJ, Kay JA, Grady CL, Fewster P, et al. Post-mortem neurofibrillary tangle densities but not senile plaque densities are related to regional metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration. 1992;1:113-121
46. Mielke R, Schröder R, Fink GR, Kessler J, Herholz K, Heiss W. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease. Acta Neuropathol. 1996;91:174-179 (Pubitemid 26021405)
47. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36:811-822
48. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462-466 (Pubitemid 26324044)
49. Nestor PJ, Balan K, Cheow HK, Fryer TD, Knibb JA, Xuereb JH, et al. Nuclear imaging can predict pathologic diagnosis in progressive nonfluent aphasia. Neurology. 2007;68:238-239 (Pubitemid 46105746)
50. Henkel K, Zerr I, Hertel A, Gratz KF, Shröter A, Tschampa HJ, et al. Positron emission tomography with [18F]FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD). J Neurol. 2002; 249:699-705. (Pubitemid 34651751)
51. Engler H, Lundberg PO, Ekbom K, Nennesmo I, Nilsson A, Berström M, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging. 2003;30:85-95. (Pubitemid 36692897)
52. Salmon E, Sadzot B, Maquet P, Degueldre C, Lemaire C, Rigo P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med. 1994;35:391-398 (Pubitemid 24079962)
53. Foster NL, Gilman S, Berent S, Sima AAF, D'Amato C, Koeppe RA, et al. Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. J Neurol Neurosurg Psychiatry. 1992;55:707-713
54. Mishina M, Ishii K, Mitani K, Ohiama M, Yamazaki M, Ishiwata K, et al. Midbrain hypometabolism as early diagnostic sign for progressive supranuclear palsy. Acta Neurol Scand. 2004;110: 128-135 (Pubitemid 39044051)
55. Arvanitakis Z,Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, et al. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord. 2007;13:230-239 (Pubitemid 46603038)
56. Silverman DHS, Small GW, Chang CY, Lu CS, Kung De Abarto MA, ChenW, et al. Positron emission tomography in evaluation of dementia; regional brain metabolism and long-term outcome. JAMA. 2001;286:2120-2127
57. Hoffman JM, Welsh-Bohmer KA, Hanson M, Krain B, Hulette C, Earl N, et al. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med. 2000;41:1920-1928
58. Minoshima S, Foster NL, Sima AAF, Frey KA, Albin RL, Kuhl DE. Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358-365 (Pubitemid 32848738)
59. Jagust W, Reed B, Mungas D, Ellis W, DeCarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871-877 (Pubitemid 47329586)
60. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007; 130:2616-2635 (Pubitemid 47511706)
61. Herzholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-316
62. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine N, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148:379-397 (Pubitemid 351665469)
63. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate to severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8): 519-526 (Pubitemid 47403186)
64. Dusseault FP, Nguyen VH, Ratchet F. La tomographie par émission de positrons au Québec. Québec (Canada): Agence d'évaluation des technologies et des modes d'intervention en santé; 2001 oct. Report No: AÉTMIS 01-3 RF. Rapport présenté au ministre délégué à la recherche, à la science et à la technologie du Québec.
65. Paquet N, Primeau F, Paradis V, Routhier G, Simard M, Bouchard RW. Comparative value of 99mTc-ECD SPECT and 18FDG PET in atypical dementia: a pilot study with longitudinal followup. Eur J Nucl Med. 2008;35:S315.
66. Silverman DH, Small GW, Phelps ME. Clinical value of neuroimaging in the diagnosis of dementia. Sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging. 1999;2:119-130
67. Massa C, Perani D, Lucignani G, Zenorini A, Zito F, Rizzo G, et al. High-resolution Technetium-99m-HMPAO SPECT in patients with probable Alzheimer's disease: comparaison with Fluorine-18-FDG PET. J Nucl Med. 1994;35:210-216 (Pubitemid 24048307)
68. Wahlund LO, Almkvist O, Blennow K, Engedahl K, Johansson A, Waldemar G, et al. Evidence-based evaluation of magnetic resonance imaging as a diagnostic tool in dementia workup. Top Magn Reson Imaging. 2005;16:427-437 (Pubitemid 44699400)
69. Chow T. Structural neuroimaging in the diagnosis of dementia. Alzheimers Dement. 2007;3:333-335 (Pubitemid 47535137)
70. Tedeschi E, Hasselbalch SG,Waldemar G, Juhler M, Høgh P, Holm S, et al. Heterogenous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry. 1995; 59:608-615